Chemomab Therapeutics

Company snapshot

Chemomab (Nasdaq: CMMB) is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chemomab Therapeutics. Not investment advice.

• Peer + 0 momentum

  Galmed Pharmaceuticals

  TA overlap score 22.6

Recent activity

Latest pipeline, patent, and corporate events for Chemomab Therapeutics.

1. Jun 8, 2026 Clinical update

   Anti-human CCL24 monoclonal antibody (CM-101) — Phase 2

2. Jun 8, 2026 Clinical update

   Anti-human CCL24 monoclonal antibody (CM-101) - Part One — Phase 1

3. Jun 8, 2026 Clinical update

   Anti-human CCL24 monoclonal antibody (CM-101) — Phase 1

4. Jun 5, 2026 Clinical update

   CM-101 — Phase 1

5. Jun 5, 2026 Clinical update

   5 mg/kg CM-101 — Phase 2

View all clinical trial activity →

• What is Chemomab Therapeutics?

  Chemomab Therapeutics is a pharma organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker CMMB. Primary therapeutic focus areas include Systemic Sclerosis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Primary Sclerosing Cholangitis, Nonalcoh

• Is Chemomab Therapeutics publicly traded?

  Yes. Chemomab Therapeutics is listed with ticker CMMB on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Chemomab Therapeutics develop or market?

  We link 4 drug profile(s) where Chemomab Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chemomab-therapeutics#company-drugs.

• What are the latest developments for Chemomab Therapeutics?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chemomab Therapeutics focus on?

  Chemomab Therapeutics focuses on Systemic Sclerosis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease based on our analysis of their pipeline programs and drug development activities.